Loading…
Scinai Immunotherapeutics Ltd. is projected to decline to $0.2314 by 2027, a -15% move from its current price of $0.273. SCNI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2617 | $0.2727 | $0.2841 | -0.11% |
| Aug 6 | $0.2571 | $0.2724 | $0.2886 | -0.22% |
| Aug 7 | $0.2534 | $0.2721 | $0.2921 | -0.33% |
| Aug 8 | $0.2504 | $0.2718 | $0.295 | -0.44% |
| Aug 9 | $0.2477 | $0.2715 | $0.2975 | -0.56% |
| Aug 10 | $0.2453 | $0.2712 | $0.2998 | -0.67% |
| Aug 11 | $0.243 | $0.2709 | $0.3019 | -0.78% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.243 | $0.2709 | $0.3019 | -0.78% |
| Week 2 | $0.2306 | $0.2688 | $0.3133 | -1.55% |
| Week 3 | $0.221 | $0.2667 | $0.3218 | -2.31% |
| Week 4 | $0.213 | $0.2646 | $0.3287 | -3.07% |
| Week 5 | $0.206 | $0.2626 | $0.3346 | -3.83% |
| Week 6 | $0.1997 | $0.2605 | $0.3398 | -4.57% |
| Week 7 | $0.194 | $0.2585 | $0.3444 | -5.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies.
It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd.
in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
SCNI is a healthcare stock currently trading at $0.2667. It carries a market capitalization of $1.38M and is ranked 5481. The forecast suggests a mixed near-term path with neutral momentum in 2026 (avg $0.2667) and changing sentiment in subsequent years, including bearish readings in 2027 and neutral readings in 2028–2029, before turning more bullish in the 2030s and 2040s.
The 2030 avg price is $0.3083 with ROI 15.6, the 2040 avg price is $0.381 with ROI 42.9, and the 2050 avg price is $0.6494 with ROI 143.5. Near-term technicals point to a 30-day trading range roughly between $0.2011 and $0.3537, with a current 30-day sentiment labeled NEUTRAL. The stock’s near-term indicators include RSI(14) at 50, SMA50 at $0.3341, and SMA200 at $0.7383, with support at $0.23 and resistance at $0.347.
A major floor 33.0% below — a decisive break under it would weaken the trend.
The nearest floor, 15.8% below — buyers have tended to step in here.
The nearest ceiling, 17.9% above — a clean break opens room to run.
A major ceiling 171.1% above — clearing it would confirm fresh momentum.
Key SCNI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCNI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2654 | Buy | $0.2662 | Buy |
| MA 10 | $0.2548 | Buy | $0.2606 | Buy |
| MA 20 | $0.2551 | Buy | $0.2658 | Buy |
| MA 50 | $0.3237 | Sell | $0.3334 | Sell |
| MA 100 | $0.4695 | Sell | $0.4719 | Sell |
| MA 200 | $0.7274 | Sell | $0.8279 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.37 | Neutral |
| Stoch RSI (14) | 94.76 | Sell |
| CCI (20) | 117.07 | Buy |
| Williams %R (14) | -6.52 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 3.80 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 93.48 | Sell |
| TRIX (15) | -1.22 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 61.27 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 0.28 | Sell |
| ADX (14) | 23.81 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50, SMA50 is $0.3341, and SMA200 is $0.7383. The thirty-day range spans from $0.2011 to $0.3537, highlighting a relatively tight band around the current price. Support is indicated at $0.23 and resistance at $0.347.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.23 | $0.273 | $0.3114 | 0% | Neutral | |
| $0.1762 | $0.2314 | $0.3259 | -15% | Bearish | |
| $0.1753 | $0.2408 | $0.3574 | -12% | Neutral | |
| $0.1879 | $0.2679 | $0.4142 | -2% | Neutral | |
| $0.2131 | $0.3143 | $0.5024 | +15% | Neutral | |
| $0.205 | $0.3119 | $0.5133 | +14% | Neutral | |
| $0.1982 | $0.3103 | $0.5241 | +14% | Neutral | |
| $0.1783 | $0.2871 | $0.4962 | +5% | Neutral | |
| $0.1615 | $0.2669 | $0.4713 | -2% | Neutral | |
| $0.2042 | $0.3462 | $0.6235 | +27% | Bullish | |
| $0.2046 | $0.3911 | $0.7638 | +43% | Bullish | |
| $0.3045 | $0.6767 | $1.48 | +148% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.23 | $0.273 | $0.3319 | +0.00% |
| September 2026 | $0.2126 | $0.255 | $0.317 | -6.58% |
| October 2026 | $0.2034 | $0.2466 | $0.3115 | -3.31% |
| November 2026 | $0.2047 | $0.2503 | $0.3202 | +1.51% |
| December 2026 | $0.1953 | $0.2407 | $0.3114 | -3.84% |
Click any year to see its month-by-month SCNI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SCNI price prediction for 2026 points to an average of $0.273 (low $0.23, high $0.3114) — a potential gain of 0% on today's $0.273. Price action looks broadly range-bound.
In 2027, SCNI is projected to trade between $0.1762 and $0.3259, averaging $0.2314 — a potential decline of -15% from today's $0.273. That is -15% versus the projected 2026 average. Expect choppier, lower action through this leg of the cycle.
Scinai Immunotherapeutics Ltd.'s 2028 outlook centres on $0.2408, within a $0.1753 to $0.3574 range. That is up +4% on the projected 2027 average. That marks a -12% change versus current levels. Price action looks broadly range-bound.
By 2029, SCNI could reach as high as $0.4142, with a base case around $0.2679 and support toward $0.1879 — roughly -2% from $0.273. A consolidation phase looks the most probable path here.
Expect SCNI to range from $0.2131 to $0.5024 through 2030. The $0.3143 average target implies a +15% move from current prices. That is up +17% on the projected 2029 average. Price action looks broadly range-bound.
The SCNI price prediction for 2031 points to an average of $0.3119 (low $0.205, high $0.5133) — a potential gain of +14% on today's $0.273. A consolidation phase looks the most probable path here.
In 2032, SCNI is projected to trade between $0.1982 and $0.5241, averaging $0.3103 — a potential gain of +14% from today's $0.273. That is 0% versus the projected 2031 average. Price action looks broadly range-bound.
Scinai Immunotherapeutics Ltd.'s 2033 outlook centres on $0.2871, within a $0.1783 to $0.4962 range. That is -7% versus the projected 2032 average. That marks a +5% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, SCNI could reach as high as $0.4713, with a base case around $0.2669 and support toward $0.1615 — roughly -2% from $0.273. Price action looks broadly range-bound.
Expect SCNI to range from $0.2042 to $0.6235 through 2035. The $0.3462 average target implies a +27% move from current prices. That is up +30% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SCNI price prediction for 2040 points to an average of $0.3911 (low $0.2046, high $0.7638) — a potential gain of +43% on today's $0.273. Momentum favours further upside here.
In 2050, SCNI is projected to trade between $0.3045 and $1.48, averaging $0.6767 — a potential gain of +148% from today's $0.273. That is up +73% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SCNI today (≈ 3,663.003663 SCNI) could be worth
$2,478.62
+$1,478.62 (+148%) by 2050 · US Dollar
Based on the average projected SCNI price of $0.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCNIwould be worth at today's price.
$1,000 invested in SCNI on Jul 31, 2025 (≈ 684.931489 SCNI) would be worth
$186.99
-$813.01 (-81.3%) today · 0.19× · US Dollar
Based on a SCNI entry price of $1.46 vs. today's $0.273.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.23 | $1,186.96 | +18.7% |
| 1 month ago | $0.272 | $1,003.68 | +0.4% |
| 3 months ago | $0.71 | $384.51 | -61.5% |
| 6 months ago | $0.99 | $275.76 | -72.4% |
| 1 year ago | $1.46 | $186.99 | -81.3% |
| All time (5.0y) ago | $275 | $0.99 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCNI forecast.
Our base-case forecast reaches $0.55 around 2050.
Implied market cap at $0.55: $2.84M
The multi-year forecast shows a gradual lift in value with key milestones in the 2030s and beyond. In 2030, the avg price is $0.3083 with ROI 15.6 and sentiment NEUTRAL. In 2040, the avg price rises to $0.381 with ROI 42.9 and sentiment BULLISH.
By 2050, the avg price reaches $0.6494 with ROI 143.5 and sentiment BULLISH. These figures imply an improving price path from mid-2020s levels toward the late 2030s and 2050, with larger upside potential in the 2040s and 2050s. Early years show smaller averages and mixed sentiment before turning more favorable in the 2035–2050 window, though these are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg $0.3083, min $0.2063, max $0.4991; ROI 15.6; sentiment NEUTRAL.
Forecast shows mixed signals: -2027 ROI -15.7 (BEARISH), -2028 ROI -11.5 (NEUTRAL), -2029 ROI -3.2 (NEUTRAL); but 2030 onward includes positive ROIs (e.g., 15.6 in 2030, 42.9 in 2040, 143.5 in 2050) with NEUTRAL to BULLISH sentiment in later years.
Yes, the forecast maximum by 2050 is $1.45.
Thirty-day range low $0.2011, high $0.3537.
2030 avg $0.3083 with ROI 15.6; 2040 avg $0.381 with ROI 42.9; 2050 avg $0.6494 with ROI 143.5; sentiments: NEUTRAL for 2030, BULLISH for 2040 and 2050.
Scinai Immunotherapeutics Ltd. Community Discussion
0Share your Scinai Immunotherapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.